Lidorestat

Drug Profile

Lidorestat

Alternative Names: EML 676; IDD 676; lindolrestat; lindorestat

Latest Information Update: 26 Oct 2005

Price : $50

At a glance

  • Originator Institute for Diabetes Discovery LLC
  • Class Antihyperglycaemics; Indoleacetic acids; Small molecules; Thiazoles
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Clinical Phase Unknown Diabetic neuropathies

Most Recent Events

  • 28 Sep 2005 A preclinical study has been added to the pharmacokinetics and Diabetes pharmacodynamics sections
  • 31 Aug 2005 The Institute for Diabetes Discovery and Alinea Pharmaceuticals have entered into an agreement to co-develop lidorestat for diabetic complications
  • 20 Sep 2004 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top